Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGuangzhou, China– June 2 , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosesimilars, will present aposter at the 2024 ASCO Annual Meeting entitled “Phase 1 study of BAT8006, afolate receptor α antibo...
Bio-Theraand STADA h ave reached an exclusive commercialization and license agreement forBAT2506, a biosesimilar candidate to Simponi ® (golimumab) Bio-Thera will maintain responsibility fordevelopment, manufacturing, and supply of BAT2506 STADA willhave exclusive rights to commercialize the product ...
GUANGZHOU, China - Bio-Thera Solutions (688177.S H ), a commercial-stage biopharmaceutical company developinginnovative therapies and biosesimilars, announced that its partner, Biogen Inc.(Nasdaq: BIIB) officially launched TOFIDENCE (tocilizumab-bavi) intravenousformulation, a biosesimilar monoclonal an...
